.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,364,620

« Back to Dashboard

Claims for Patent: 5,364,620

Title: Controlled absorption diltiazem formulation for once daily administration
Abstract:A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration.
Inventor(s): Geoghegan; Edward J. (Athlone, IE), Mulligan; Seamus (Athlone, IE), Panoz; Donald E. (Tuckerstown, BN)
Assignee: Elan Corporation, Plc (Westmeath, IE)
Application Number:07/921,459
Patent Claims: 1. A method of treating or controlling blood pressure in a subject suffering from mild to moderate hypertension, comprising administering to said subject on a once per day basis a dose effective to lower the blood pressure of said subject throughout said twenty four hour period, of a diltiazem-containing controlled absorption formulation to provide peak blood pressure lowering levels in the blood 6 to 18 hours following administration, said formulation comprising pellets having a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, the diltiazem component and the organic acid being present in a ratio of from about 20:1 to about 1:1, and a multi-layer membrane surrounding said core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer.

2. The method of claim 1 wherein said formulation further comprises a sufficient quantity of a rapid release form of diltiazem formulated to provide am effective blood pressure lowering amount of diltiazem within one hour following administration.

3. The method of claim 2 wherein said formulation contains up to about 25 % by weight of said rapid release form of diltiazem.

4. A method of controlling or preventing angina attacks or reducing the incidence of angina attacks in a subject suffering from angina pectoris, comprising administering to said subject on a once per day basis a dose effective to improve the blood supply and hence increase the oxygen supply in the myocardium of said subject throughout said twenty four hour period of a diltiazem-containing controlled absorption formulation to provide peak myocardium oxygenating levels in the blood 6 to 18 hours following administration, said formulation comprising pellets having a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, the diltiazem component and the organic acid being present in a ratio of from about 20:1 to about 1:1, and a multi-layer membrane surrounding said core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic. polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer.

5. The method of claims 4 wherein said formulation further comprises a sufficient quantity of a rapid release form of diltiazem effective to increase the oxygen supply to the myocardium within one hour following administration.

6. The method of claim 5 wherein said formulation contains up to about 25% by weight of said rapid release form of diltiazem.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc